- Home
- ISPC vs GOVX Comparison
ISPC vs GOVX Comparison
Compare ISPC & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ISPC | GOVX |
|---|---|---|
| Founded | 2009 | 2001 |
| Country | United States | United States |
| Employees | 24 | N/A |
| Industry | Precision Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 2.7M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ISPC | GOVX |
|---|---|---|
| Price | $0.25 | $1.62 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $200.00 |
| AVG Volume (30 Days) | ★ 934.2K | 133.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,291,115.00 | N/A |
| Revenue This Year | $35.93 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.23 | $0.12 |
| 52 Week High | $2.16 | $4.40 |
Technical Indicators
Market Signals| Indicator | ISPC | GOVX |
|---|---|---|
| Relative Strength Index (RSI) | 37.70 | 41.37 |
| Support Level | N/A | $0.55 |
| Resistance Level | $0.44 | $4.40 |
| Average True Range (ATR) | 0.03 | 0.25 |
| MACD | -0.00 | -0.10 |
| Stochastic Oscillator | 14.02 | 24.01 |
Price Performance
Historical ComparisonAbout ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.